KZR241220C2500
- 0.00
- 0.000.00%
Kezar Life Sciences Newsroom
KEZAR MARKETS ANNOUNCES RETIREMENT OF CEO WHIT CONARY & NAMES STEVE MIELE AS THE NEW CHIEF EXECUTIVE OFFICER
Express News | Kezar Life Sciences Inc: On November 13, Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Cuts Target Price to $11
TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
Kezar Life Sciences (KZR) Receives a Buy From TD Cowen
Express News | Kezar Life Sciences Inc : Jefferies Cuts Target Price to $18 From $30
Kezar Life Sciences | 10-Q: Q3 2024 Earnings Report
Kezar Life Sciences Reports Q3 EPS ($2.78), Consensus ($3.15)
Kezar Life Sciences | 8-K: Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Press Release: Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences 3Q Loss/Shr $2.78 >KZR
Express News | Kezar Life Sciences Q3 Operating Income USD -21.948 Million
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Looking Into Kezar Life Sciences's Recent Short Interest
Kezar Life Sciences To Carry Out 1-for-10 Reverse Stock Split On October 30th, 2024
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split >KZR